Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1.

The Snail family transcriptional repressor 1 gene (Snail1) was screened in multiple myeloma cells (MMCs) from bortezomib-resistant MM patients and was found to be significantly associated with the development of drug-resistance mechanisms. In the present study, we first confirmed that the protein expression of Snail1 in bortezomib-resistant MMCs was significantly higher than that in MMCs without bortezomib resistance. The mechanistic studies confirmed that the enhancement of Snail1 expression in bortezomib-resistant MMCs directly upregulated transcription of the intracellular MDR1 gene to immediately develop multiple drug resistance mechanisms and inhibited P53 protein expression through the Snail1/hsa-miRNA-22-3p/P53 pathway to inhibit tumor cell apoptosis. By upregulating MDR1 and downregulating P53, Snail1 induced the drug resistance of MMCs to bortezomib, while Snail1 gene silencing effectively improved the drug sensitivity of MMCs to bortezomib chemotherapy. The present study further elucidated the drug resistance mechanisms of MMCs and provides evidence for increased clinical efficacy of bortezomib in MM patients.

[1]  P. Sonneveld,et al.  Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. , 2018, Pharmacogenomics.

[2]  P. Kischel,et al.  Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection , 2018, Cell Death & Differentiation.

[3]  A. Lamprecht,et al.  MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. , 2017, Pharmacological research.

[4]  J. Delabie,et al.  MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma , 2017, Blood Cancer Journal.

[5]  Vildan Bozok ÇetİntaŞ,et al.  Current updates on microRNAs as regulators of chemoresistance. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Tao Wu,et al.  Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report , 2017, Oncology letters.

[7]  P. Sonneveld,et al.  Potential Therapeutic and Economic Value of Risk-Stratified Treatment as Initial Treatment of Multiple Myeloma in Europe , 2017 .

[8]  A. Scherbakov,et al.  Horizontal Transfer of Tamoxifen Resistance in MCF-7 Cell Derivates: Proteome Study , 2017, Cancer investigation.

[9]  S. Luanpitpong,et al.  Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma , 2017, Scientific Reports.

[10]  T. Ogihara,et al.  Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells. , 2017, Journal of pharmaceutical sciences.

[11]  Ji-Young Hong,et al.  The role of exosomes and miRNAs in drug‐resistance of cancer cells , 2017, International journal of cancer.

[12]  Heribert Hirt,et al.  The heat‐shock protein/chaperone network and multiple stress resistance , 2017, Plant biotechnology journal.

[13]  N. Zhang,et al.  Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance , 2017, Leukemia & lymphoma.

[14]  J. Haigh,et al.  The Snail Family in Normal and Malignant Haematopoiesis , 2017, Cells Tissues Organs.

[15]  M. Dimopoulos,et al.  Efficacy and safety of elotuzumab for the treatment of multiple myeloma , 2017, Expert opinion on drug safety.

[16]  Honghe Zhang,et al.  Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review) , 2016, International journal of oncology.

[17]  A. Brozovic.  The relationship between platinum drug resistance and epithelial–mesenchymal transition , 2016, Archives of Toxicology.

[18]  A. Armstrong,et al.  Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer , 2016, Oncotarget.

[19]  Jie Huang,et al.  MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN. , 2016, Molecular medicine reports.

[20]  Michael R. Mancuso,et al.  Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. , 2016, Current problems in cancer.

[21]  S. Farajnia,et al.  New insights into the mechanisms of multidrug resistance in cancers. , 2015, Cellular and molecular biology.

[22]  N. Nikesitch,et al.  Molecular mechanisms in multiple myeloma drug resistance , 2015, Journal of Clinical Pathology.

[23]  W. Fulp,et al.  A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma , 2015, Cancer.

[24]  Su-Jin Lee,et al.  NF2 blocks Snail-mediated p53 suppression in mesothelioma , 2015, Oncotarget.

[25]  Karl A. Merrick,et al.  A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. , 2014, Cancer cell.

[26]  Su-Jin Lee,et al.  NF 2 blocks Snail-mediated p 53 suppression in mesothelioma , 2015 .

[27]  Hongyan Wang,et al.  Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line. , 2014, Molecular medicine reports.

[28]  K. Bowles,et al.  Overcoming bortezomib resistance in multiple myeloma. , 2014, Biochemical Society transactions.

[29]  Hao Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. , 2014, European journal of pharmacology.

[30]  Guoan Chen,et al.  Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms , 2013, Oncotarget.

[31]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[32]  Z. Čermáková,et al.  [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials]. , 2013, Vnitrni lekarstvi.

[33]  N. Nonomura,et al.  Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. , 2012, Oncology letters.

[34]  J. Abrams,et al.  Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma , 2012, Journal of chemotherapy.

[35]  S. Thomson,et al.  Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model , 2011, Clinical & Experimental Metastasis.

[36]  V. Odero-Marah,et al.  Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. , 2011, Biochemical and biophysical research communications.

[37]  H. Jäck,et al.  Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. , 2007, Cancer research.

[38]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[39]  M. Hendrix,et al.  Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.

[40]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[41]  D. Chauhan,et al.  Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications , 2003, Apoptosis.

[42]  M. Nieto,et al.  The snail superfamily of zinc-finger transcription factors , 2002, Nature Reviews Molecular Cell Biology.

[43]  Dihua Yu,et al.  Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down‐regulating multidrug resistance‐1 expression , 2001, Cancer.

[44]  C. Yue,et al.  Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene , 2001, Oncogene.

[45]  E. Schuetz,et al.  p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.